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Background: Weight gain can contribute towards the development of type 2 diabetes (T2D), 
and some treatments for T2D can lead to weight gain. The aim of this study was to determine 
whether having T2D and also being obese had a greater or lesser impact on health-related quality 
of life (HRQoL) than having either of the two conditions alone.
Methods: The 2003 dataset of the Health Survey for England (HSE) was analyzed using 
multiple regression analyses to examine the influence of obesity and T2D on HRQoL, and to 
determine whether there was any interaction between these two disutilities.
Results: T2D reduced HRQoL by 0.029 points, and obesity reduced HRQoL by 0.027 points. 
There was no significant interaction effect between T2D and obesity, suggesting that the effect 
of having both T2D and being obese is simply additive and results in a reduction in HRQoL 
of 0.056.
Conclusions: Based on analysis of HSE 2003 data, people with either T2D or obesity experience 
significant reduction in HRQoL and people with both conditions have a reduction in HRQoL 
equal to the sum of the two independent effects. The effect of obesity on HRQoL in people with 
T2D should be considered when selecting a therapy.
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Background
Obesity and type 2 diabetes (T2D) are two world health concerns of pressing 
importance, with the prevalence of both increasing at a startling rate. It is estimated by 
the International Diabetes Foundation (IDF) that the that the global number of adults 
with Type 1 diabetes (T1D) or T2D will grow from 248 million in 2007 to 380 million 
in 2025.1 Currently, in developed countries, 85% to 95% of people with diabetes have 
T2D, and in developing countries the proportion with T2D (compared with T1D) is 
higher.1,2 The World Health Organization (WHO) estimated that in 2005 there were 
more than 400 million obese adults, with body mass index (BMI) > 30 kg/m2, and 
1.6 billion overweight adults.3 According to the latest Quality and Outcomes Framework 
(QOF) estimates, the prevalence of T1D and T2D in England was 3.9% in 2008 (data for 
T2D alone are not recorded, but are approximately 90% of all cases) and the prevalence 
of obesity was 7.66% – the prevalence of both are increasing each year.4
Both T2D5 and obesity6 reduce HRQoL. The gravest affect of T2D is due to 
the macro- and micro-vascular complications which usually develop as the disease 
progresses.7,8 Obese people suffer from impaired HRQoL due to specific problems 
relating to mobility, pain, and/or discomfort,9 but also as a result of increased risk of 
T2D, coronary heart disease (CHD), and hypertension.6,10Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 180
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Obesity and T2D are also closely related, since obesity 
is the largest risk factor for developing T2D.11 Therefore, 
first-line intervention in the management of T2D includes 
diet and exercise in an attempt to promote weight loss. 
Unfortunately, however, many of the agents available for 
the management of T2D often lead to weight gain.12,13 Thus 
knowledge of the relationship between T2D, obesity and 
HRQoL is desirable.
Several studies have separately investigated weight 
or diabetes and their effect on HRQoL, but the available 
literature examining the simultaneous effects of weight and 
diabetes on HRQoL is limited.14 Cross-sectional data are 
needed to extend the knowledge in this area.
The aim of this study was to evaluate the relationship 
between obesity, T2D, and HRQoL in a real-world setting 
in the general population of England.
Methods
We used data collected during the Health Survey for England 
(HSE) 2003.15 The HSE is a series of annual surveys, commis-
sioned by the UK Department of Health, which covers people 
living in private households in England. Data collection for 
HSE 2003 involved an interview, followed by a visit from 
a specially trained nurse, and included weight and height 
measurements, as well as further questioning.
Each year the HSE focuses on a different demographic 
group and looks at health indicators such as cardiovascular 
disease, physical activity, eating habits, oral health, accidents, 
and asthma. The 2003 survey had a primary focus on cardio-
vascular problems and a secondary focus on diabetes. It also 
included the EQ-5D questionnaire,16 a generic health-related 
quality-of-life measure. The HSE 2003 dataset therefore con-
tained all the parameters for studying the effects of weight, 
diabetes, confounding illness, and social factors on HRQoL.
The EQ-5D questionnaire is standardized for use as a 
measure of HRQoL. It provides a simple descriptive profile 
and a single index value for health status. Each of the five 
domains consists of three levels (ie, rated by individuals 
as ‘no problems’, ‘some/moderate problems’, or ‘extreme/
severe problems’). The five domains of the EQ-5D are: 
mobility, self-care, usual activity, pain/discomfort, and 
anxiety/depression. An individual with no problems in any 
domain would have a score of 1.0. A lower score is recorded 
if the individual has lower HRQoL, and death is scored as 0.0. 
Values below zero can exist, if in a given situation, death 
is considered favorable to life in that given health state. 
To derive utilities, each health state has been assigned a value 
based on a UK time-trade-off survey.17
During data collection for HSE 2003, participants in the 
survey were asked if they had diabetes, but not whether they 
had T1D or T2D. A post-hoc interpretation was applied by 
those collecting the data, whereby if a participant was receiv-
ing insulin at the time of interview, and had been diagnosed 
with diabetes before their 35th birthday, they would be 
categorized as having T1D. Otherwise they were categorized 
as having T2D. Obesity was defined as BMI  30 kg/m2 
and overweight as BMI of 25 to 29.9 kg/m2 according to the 
WHO classification.3,11
The original HSE 2003 dataset (18,553 responses) was 
purged of records from participants that did not receive the 
EQ-5D questionnaire (those  16 years old), or did not 
complete it; who had T1D; or did not provide measurements 
needed to calculate BMI. Also discarded were: data from 
participants who failed to inform about smoking status, car-
diovascular disease history, blood pressure, history of long 
standing, or recent acute illnesses, and participants who did 
not fill out the General Health Questionnaire (GHQ) (which 
is designed to predict the need for psychological help).18 
The GHQ is a validated, self-administered, 12-items question-
naire focusing on the inability to carry out normal functions 
and the appearance of new and distressing phenomena.19 After 
purging the dataset, the final number of respondents included 
in the analyses was 12,188, of which 373 (3.1%) had T2D.
A multiple linear regression model, consisting of vari-
ables describing several factors such as physical and mental 
well-being, and socio-economic status, and including infor-
mation on diabetes and BMI, was developed for this study. 
In the model, HRQoL was dependent on socio-economic and 
health factors and, for analytical purposes, the focus was on 
variables for weight and diabetes.
The dataset was analyzed using multiple linear regres-
sion analysis to examine the influence of obesity and T2D on 
HRQoL. Age and gender were retained, even if they became 
statistically insignificant. Whether or not all other variables 
were retained depended on the statistical tests. The interac-
tion between the two disutilities, diabetes and obesity, was 
analyzed to determine whether being obese and having T2D 
had a further effect beyond the additive effects of having 
each condition.
The regression model also included variables for socio-
economic status (income), as well as lifestyle indicators 
affecting health (smoking), and multiple indicators of health 
status and wellbeing. An acute illness variable described 
any recent medical history, and a GHQ score measured 
mental wellbeing. Comorbidity variables contained vari-
ous long-term medical conditions that could affect HRQoL Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 181
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(such as kidney disease, rheumatism, asthma, back problems, 
bronchitis, cancer, epilepsy, hearing problems, ulcer, 
cardiovascular disease, and hypertension; Table 2). When 
testing for statistical significance, some variables were 
treated as groups (income, smoking, acute illness, and GHQ). 
Comorbidities were tested individually.
Results
Demographics
T2D was primarily present in participants over 40 years of 
age, and most frequently in people over 60 years (Table 1). 
Approximately 50% of people with T2D were also obese, 
and normal weight individuals had the lowest prevalence of 
T2D. The trend of higher T2D prevalence with higher BMI 
group was consistent across age groups, with the exception 
of the 16–29 year age group, where very small numbers of 
people with T2D produced inconsistent results, as shown 
in Table 1.
Regression analysis
In the model, both T2D and obesity had significant, 
independent effects on HRQoL, measured by the EQ-5D. 
Having T2D reduced HRQoL by 0.029 points and obesity 
reduced HRQoL by 0.027 points. The analysis showed no 
significant interaction effect between T2D and obesity. The 
effect of having both conditions is simply the sum of each 
individual effect (-0.056; Figure 1).
Compared with people whose income was in the lowest 
fifth of the population, people with higher incomes tended 
to have a better HRQoL.
Compared with current smokers, people who had 
stopped smoking, or never started, had a statistically better 
HRQoL.
Recent suffering from an acute illness, reduced health-
related HRQoL, and participants who had a high score on the 
GHQ (indicating mental problems) also had reduced HRQoL. 
Having other co-morbidities decreased HRQoL, except for 
hearing problems, which had a positive effect on HRQoL. 
Also, HRQoL decreased as people got older (Table 2).
Discussion
This study showed that obese people (BMI  30 kg/m2) 
had a lower HRQoL than non-obese people, regardless of 
whether they have T2D or not. People with T2D, with normal 
weight (BMI < 25 kg/m2), or obesity, had a lower HRQoL 
than those in the same weight groups, without the disease. 
However, the effect of obesity and T2D is purely additive, 
with no positive or negative effects of having both conditions 
at the same time.
These results support those from previous investigations 
of the impact on HRQoL of obesity and T2D.20 A study by 
Macran9 that also used HSE data (1996) to examine the rela-
tionship between weight (BMI) and HRQoL (with HRQoL 
quantified according to EQ-5D) found a significant difference 
in HRQoL between BMI categories, although results differed 
by gender. For women, but not men, there was a significant 
decrease in utility scores with increasing BMI, when adjusted 
for age and longstanding illness.9
In a study by Lee et al,21 increasing BMI was found to 
reduce utility in each of the three groups T1D, T2D, and no 
Table 1 number and proportion of people with type 2 diabetes (T2D) per age and weight group in health Survey for england 2003
BMI  25 kg/m2 BMI 25.0-29.9 kg/m2 BMI ≥ 30 kg/m2 All weight groups
16–29 years All, n 1390 568 266 2224
With T2D, n 2 0 3 5
Proportion with T2D, % 0.1 0.0 1.1 0.2
30–49 years All, n 1780 1765 1084 4629
With T2D, n 6 14 29 49
Proportion with T2D, % 0.3 0.8 2.7 1.1
50–69 years All, n 1071 1674 1073 3818
With T2D, n 23 56 108 187
Proportion with T2D, % 2.1 3.3 10.1 4.9
70+ years All, n 456 661 400 1517
With T2D, n 23 62 47 132
Proportion with T2D, % 5.0 9.4 11.8 8.7
All ages All, n 4697 4668 2823 12188
With T2D, n 54 132 187 373
Proportion with T2D, % 1.1 2.8 6.6 3.1Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 182
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diabetes. The effect of both BMI and diabetes on utility was 
significant. There was no significant difference in the effect of 
obesity on utility between those with and without diabetes.
A recent review of 18 articles investigating the impact 
of change in body weight on people’s utility scores found 
that utility decreased as body weight increased, regardless 
of the scoring system used, or the population.14 The review 
also found that the change in utility score per unit change 
in BMI, was slightly higher in people with diabetes than in 
people without diabetes.14 Our results support the findings 
of Matza et al,22 who showed that a 3% higher weight (as a 
treatment-related attribute) was accompanied by a reduction 
in HRQoL of 0.04 points.
The reduction in HRQoL associated with having T2D 
and obesity shown in this study was similar to the impact of 
aging several decades, or going from having an income in 
the second highest quintile to being in the lowest quintile. 
The impact was slightly lower than the impact of a foot 
ulcer and slightly greater than the impact of a cardiovas-
cular event.
Table 2 Overview of results from the regression model
Parameter estimate Standard error
intercept 0.976 0.006
Age last birthday –0.001 0.000
Female –0.005 0.003
Diabetes –0.029 0.001
Obese – BMi  30 –0.027 0.003
Equalized income (as opposed to lowest quintile)
  equalized income – missing 0.031 0.005
  equalized income – 2nd quintile 0.027 0.005
  equalized income – 3rd quintile 0.040 0.005
  equalized income – 4th quintile 0.056 0.005
  equalized income – top quintile 0.064 0.005
Smoking (as opposed to non-smoking)
  Smoking: ex-regular smoker 0.026 0.004
  Smoking: never smoker 0.025 0.003
Acute illness (as opposed to not having had acute  
illness in the last 2 weeks)
  Acute illness: 1–3 days -0.039 0.007
  Acute illness: 4–6 days -0.077 0.009
  Acute illness: 7–13 days -0.088 0.008
  Acute illness: a full 2 weeks -0.153 0.007
GHQ (as opposed to having a score of zero)
  GhQ: score 1–3 -0.058 0.003
  GhQ: score 4+ -0.194 0.005
Comorbidities
  Kidneys -0.063 0.016
  Rheumatism -0.169 0.005
  Asthma -0.013 0.006
  Back problems -0.137 0.006
  Bronchitis -0.130 0.015
  cancer -0.073 0.011
  epilepsy -0.080 0.016
  hearing problems 0.028 0.012
  Ulcer -0.059 0.011
  cVD (angina, heart attack or stroke) -0.048 0.006
  high blood pressure -0.017 0.004
Notes: Values in bold are statistically insignificant (ie, all values were significant [P  0.05] except those for female gender).
Abbreviations: BMi, body mass index; cVD, cardiovascular disease; GhQ, General health Questionnaire.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 183
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Although neither T2D nor obesity was correlated with an 
increase in the risk of problems in the EQ-5D sub-model on 
anxiety (results not shown), people with a high GHQ score 
(ie, people who reported a need for psychological help), had 
lower HRQoL. GHQ score could to some extent, be seen 
as a proxy for anxiety issues stemming from other sources, 
such as diabetes and obesity. This would support results 
from the Diabetes Attitudes Wishes and Needs (DAWN) 
study, in which people reported they would feel a sense of 
self-blame if they had to start insulin therapy.23 The IDF 
currently recommends that well-being and psychological 
status are periodically tested in people with T2D, either by 
questioning or using a formal instrument.24
The effect of obesity on HRQoL in people with T2D 
should be considered when selecting a therapy. Where pos-
sible, preference should be given to therapeutic interventions 
that have a minimal impact on weight gain. In the United 
Kingdom Prospective Diabetes Study (UKPDS), weight 
gain was found to be significantly higher in people with 
T2D receiving intensive treatment than in those receiving 
conventional treatment.25 It is recognized that different 
treatments can have different effects in weight gain – bigu-
anides, α-glucosidase inhibitors, GLP-1 agents, and some 
insulin analogues are the least likely to cause weight gain 
and may be associated with weight loss.13,26 The results of 
the multinational DAWN study27 show that that one of the 
priorities among patients with T2D was the avoidance of 
weight gain.
People with T1D made up almost a quarter of people 
with diabetes in HSE 2003, compared with the European 
norm of 4% to 5%,28 indicating that the interpretation may 
have classified too many people as having T1D. However, 
any choice of age limit as a means of distinguishing between 
diabetes types will tend to be arbitrary and some degree of 
misclassification is unavoidable. For the purpose of this 
article the chosen standard for the HSE 2003 was used, but 
we noted the potential for misclassification and acknowledge 
that this is one of the limitations of the analysis. However, 
we do not believe that any misclassification would have had 
a substantial impact on the overall findings of this analysis.
The HSE dataset analyzed in the current study did not 
include people in institutions, which is likely to have resulted 
in a relatively lower representation of the older population, 
particularly those with disabilities and severe illness. Non-
inclusion of this population in our assessment could have 
led to an underestimation of the mean impact on HRQoL of 
both obesity and diabetes.
The prevalence of T2D was only 3.1% in the purged 
dataset, compared with 3.9% in the UK population in 2003.1 
However, it was considered that the remaining people with 
diabetes were representative of the group as a whole, and 
therefore, the selection bias would not exaggerate the results 
in the model. Similarly, approximately 34% of the HSE 
2003 population was excluded, introducing the possibility 
of non-response bias. However, most people excluded from 
the analysis were children (16 years old; 58% of those 
excluded) who did not complete the EQ-5D and would not 
have been classified as T2D patients in our analysis.
Conclusions
The results of this study of data from HSE 2003 show that 
having T2D and being obese, as individual conditions, 
reduce HRQoL significantly, but that the effect of having 
both conditions is purely additive. When we consider that 
many treatments for T2D cause weight gain, the effect of a 
treatment-related increase in weight on the HRQoL of people 
with T2D should be taken into account when choosing treat-
ment. In future, longitudinal data may provide information 
on the effect on HRQoL of treatment-associated weight gain 
on people with T2D.
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